DOW PHARM
PharmaDOW PHARM is a pharmaceutical company focused on Dermatology. Key products include ALTRENO.
DOW PHARM's Key Drugs
DOW PHARM's core commercial portfolio centers on ALTRENO, spanning Dermatology — its most strategically important drugs approved in the last 15 years.
DOW PHARM's Recent FDA Approvals
New NDA/BLA approvals for DOW PHARM over the last two years — novel drugs only, excluding generics and label supplements.
DOW PHARM's Therapeutic Areas
DOW PHARM's approved drugs and pipeline span 1 therapeutic area, led by Dermatology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
DOW PHARM's Top Competitors
DOW PHARM's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
DOW PHARM Pipeline Snapshot
DOW PHARM has 2 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 2 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ALTRENO leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1954-04-19
- Latest
- 2018-08-23
- Applications
- 9